anti-ADAM10 monoclonal antibody (Mirimus/Memorial Sloan Kettering Cancer Center/SUNY Downstate Medical Center)

N/A

Report date: 2025/06/11 10:54:53

Base Information

Drug Nameanti-ADAM10 monoclonal antibody (Mirimus/Memorial Sloan Kettering Cancer Center/SUNY Downstate Medical Center)
Drug Alias Name1H5 (Mirimus/Memorial Sloan Kettering Cancer Center/SUNY Downstate Medical Center)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionDisintegrin and metalloproteinase domain-containing protein 10 inhibitors
TargetsDisintegrin and metalloproteinase domain-containing protein 10
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMirimus IncThe State University of New York Downstate Health Sciences UniversityMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A